United Therapeutics Corporation · NASDAQ:UTHR
Rothblatt Martine A sold 9,500 United Therapeutics Corporation shares (Form 4)
Traded Oct 2, 2026 · Filed Oct 5, 2026
On Oct 2, 2026, Rothblatt Martine A (Director, Chairperson & CEO) sold 9,500 United Therapeutics Corporation shares at an average US$549.37 for US$5.22M under a trading plan, leaving 324,443 shares. Filed Oct 5, 2026 (Form 4).
- Sold
- 9,500 shares
- Price
- US$549.37 average (US$542.06 to US$574.23)
- Value
- US$5.22M
- Holding after
- 324,443 shares (held indirectly)
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director, Chairperson & CEO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | Common Stock | Option exercise | 9,500 | US$117.76 | 333,943 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 700 | US$542.06 | 333,243 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 408 | US$542.87 | 332,835 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 1,032 | US$544.17 | 331,803 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 1,280 | US$544.90 | 330,523 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 309 | US$546.75 | 330,214 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 1,171 | US$547.99 | 329,043 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 1,206 | US$548.87 | 327,837 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 757 | US$549.59 | 327,080 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 432 | US$550.99 | 326,648 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 725 | US$551.82 | 325,923 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 160 | US$552.86 | 325,763 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 80 | US$554.30 | 325,683 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 80 | US$555.60 | 325,603 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 240 | US$557.43 | 325,363 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 120 | US$558.60 | 325,243 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 120 | US$560.66 | 325,123 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 40 | US$562.35 | 325,083 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 80 | US$563.88 | 325,003 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 80 | US$566.58 | 324,923 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 240 | US$569.90 | 324,683 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 120 | US$570.70 | 324,563 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 80 | US$572.44 | 324,483 | Indirect |
| Oct 2, 2026 | Common Stock | Sale | 40 | US$574.23 | 324,443 | Indirect |
Source
Related
- United Therapeutics Corporation
- Rothblatt Martine A
- United Therapeutics Corporation shareholders
- Form 4 · Rothblatt Martine A · Oct 23, 2026
- Form 4 · Rothblatt Martine A · Oct 22, 2026
- Form 4 · Rothblatt Martine A · Oct 21, 2026
- Form 4 · Rothblatt Martine A · Oct 20, 2026
- Form 4 · Rothblatt Martine A · Oct 19, 2026
- Schedule 13G/A · Rothblatt Martine A · Aug 14, 2026
- Schedule 13G/A · Wellington Management Group LLP · Aug 13, 2026
- Schedule 13G · Vanguard Capital Management LLC · Apr 30, 2026
- Schedule 13G/A · The Vanguard Group · Mar 27, 2026
- Schedule 13G · Wellington Management Group LLP · Feb 10, 2026